Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FB
Fortress Biotech, Inc.
FBIO
Volume
223.00K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FB
FBIO
FB
Fortress Biotech, Inc.
FBIO
News
·
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Mkt Cap
$63.7M
Volume
223.00K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fortress Biotech announced that CEO Lindsay A. Rosenwald will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available on-demand starting September 11, 2026, with one-on-one meetings scheduled for September 14-16, 2026. The company continues to advance its portfolio of marketed pharmaceutical products and development programs across oncology, dermatology, and rare diseases through partnerships with leading academic and biopharmaceutical institutions.
GlobeNewswire Inc. · Sep 8, 2026
Fortress Biotech Investigated by the Portnoy Law Firm
Fortress Biotech and its subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA regarding the New Drug Application for CUTX-101, citing manufacturing facility cGMP deficiencies, which negatively impacted the company's stock price.
GlobeNewswire Inc. · Oct 1, 2025
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Fortress Biotech's subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA for CUTX-101, a drug intended to treat Menkes disease. Sentynl Therapeutics, which assumed responsibility for the drug, plans to address manufacturing facility cGMP deficiencies and resubmit the New Drug Application.
GlobeNewswire Inc. · Oct 1, 2025
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.
Benzinga · May 30, 2025
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
Fortress Biotech, an innovative biopharmaceutical company, announced the FDA approval of its drug Emrosi for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway. The company also announced a strategic collaboration with Partex NV to accelerate asset identification and evaluation using Partex's proprietary AI platform.
GlobeNewswire Inc. · May 7, 2025
Mustang Bio Announces Closing of $8 Million Public Offering
Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.
GlobeNewswire Inc. · Feb 10, 2025
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.
Benzinga · Feb 6, 2025
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock, Series C-1 warrants, and Series C-2 warrants, raising approximately $8 million in gross proceeds.
GlobeNewswire Inc. · Feb 6, 2025
Fortress Biotech CEO buys $36.7k in preferred stock - Investing.com
Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.
Investing.com · Jul 10, 2024
Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday - Greenbrier Companies (NYSE:GBX) - Benzinga
The article discusses several stocks to watch on Monday, including Greenbrier Companies, Nature Wood Group, Fortress Biotech, Sonic Automotive, and Unicycive Therapeutics.
Benzinga · Jul 8, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
FB
FBIO
Fortress Biotech, Inc.
Buy
Sell
Market
Limit
Soon
FBIO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any FBIO yet.
Related Tickers
Earnings